EE05111B1 - Interferoon-beetaga sulandatud valgud ja nende kasutamine - Google Patents

Interferoon-beetaga sulandatud valgud ja nende kasutamine

Info

Publication number: EE05111B1
Authority: EE; Estonia
Prior art keywords: beta; fusion proteins; interferon beta; interferon; polypeptide
Prior art date: 1998-10-16

Application number

EEP200100223A

Other languages

English (en)

Inventor

Whitty Adrian

Runkel Laura

Brickelmaier Margot

Hochman Paula

Original Assignee

Biogen, Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-16

Filing date

1999-10-15

Publication date

2008-12-15

1999-10-15 Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated

2002-06-17 Publication of EE200100223A publication Critical patent/EE200100223A/et

2008-12-15 Publication of EE05111B1 publication Critical patent/EE05111B1/et

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Oncology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Toxicology (AREA)
Zoology (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Hematology (AREA)

EEP200100223A 1998-10-16 1999-10-15 Interferoon-beetaga sulandatud valgud ja nende kasutamine EE05111B1 (et)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10449198P	1998-10-16	1998-10-16
US12023799P	1999-02-16	1999-02-16
PCT/US1999/024200 WO2000023472A2 (en)	1998-10-16	1999-10-15	Interferon-beta fusion proteins and uses

Publications (2)

Publication Number	Publication Date
EE200100223A EE200100223A (et)	2002-06-17
EE05111B1 true EE05111B1 (et)	2008-12-15

Family

ID=26801613

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200100223A EE05111B1 (et)	1998-10-16	1999-10-15	Interferoon-beetaga sulandatud valgud ja nende kasutamine

Country Status (28)

Country	Link
US (3)	US6800735B2 (et)
EP (1)	EP1121382B9 (et)
JP (2)	JP4761621B2 (et)
KR (1)	KR100767649B1 (et)
CN (1)	CN100480266C (et)
AT (1)	ATE327254T1 (et)
AU (1)	AU766190B2 (et)
BR (1)	BR9915548A (et)
CA (1)	CA2343094A1 (et)
CY (1)	CY1105173T1 (et)
CZ (1)	CZ300762B6 (et)
DE (1)	DE69931507T2 (et)
DK (1)	DK1121382T3 (et)
EA (1)	EA005005B1 (et)
EE (1)	EE05111B1 (et)
ES (1)	ES2265693T3 (et)
HK (1)	HK1042098B (et)
HU (1)	HUP0200414A2 (et)
IL (2)	IL142350A0 (et)
IS (1)	IS5887A (et)
MX (1)	MXPA01003790A (et)
NO (1)	NO20011861L (et)
NZ (1)	NZ510559A (et)
PL (1)	PL200586B1 (et)
PT (1)	PT1121382E (et)
SK (1)	SK287491B6 (et)
TR (1)	TR200101087T2 (et)
WO (1)	WO2000023472A2 (et)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2245052T3 (es) *	1997-12-01	2005-12-16	Fang Fang	Anticuerpos de recombinacion multivalentes destinados para el tratamiento de infecciones debidas al rinovirus humano (hrv).
EE05201B1 (et) *	1998-10-16	2009-08-17	Biogen Idec Ma Inc.	Glkoslitud interferoon-beeta, selle kasutamine ja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
EE05111B1 (et) *	1998-10-16	2008-12-15	Biogen, Incorporated	Interferoon-beetaga sulandatud valgud ja nende kasutamine
US20030035798A1 (en) *	2000-08-16	2003-02-20	Fang Fang	Humanized antibodies
US6531122B1 (en)	1999-08-27	2003-03-11	Maxygen Aps	Interferon-β variants and conjugates
US7144574B2 (en)	1999-08-27	2006-12-05	Maxygen Aps	Interferon β variants and conjugates
US7431921B2 (en)	1999-08-27	2008-10-07	Maxygen Aps	Interferon beta-like molecules
US6697363B1 (en)	2000-06-28	2004-02-24	Alcatel Canada Inc.	Method and apparatus for longest matching prefix determination in a communication network
WO2002036628A2 (en) *	2000-11-02	2002-05-10	Maxygen Aps	New multimeric interferon beta polypeptides
HRP20030426A2 (en) *	2000-12-06	2005-04-30	Applied Research Systems Ars Holding N.V.	Use of sarp-1 for the treatment and/or preventionof scleroderma
EP1399568B1 (de) *	2001-02-01	2005-11-16	Roche Diagnostics GmbH	Verfahren zur herstellung von rekombinantem trypsin
YU48703A (sh)	2001-02-27	2006-05-25	Maxygen Aps	Novi interferonu beta-slični molekuli
HUP0303534A3 (en) *	2001-03-15	2005-12-28	Merck Patent Gmbh	Modified interferon beta with reduced immunogenicity
WO2003062370A2 (en) *	2001-07-19	2003-07-31	Perlan Therapeutics, Inc.	Multimeric proteins and methods of making and using same
EP1471974B1 (en) *	2002-02-06	2007-09-19	Ares Trading S.A.	Tumor necrosis factor combined with interferon in demyelinating diseases
EP1553971A4 (en) *	2002-07-17	2006-07-05	Biogen Idec Inc	THERAPIES AGAINST KIDNEY FAILURES WITH INTERFERON-b
WO2004020468A2 (en) *	2002-08-28	2004-03-11	Maxygen Aps	Interferon beta-like molecules for treatment of cancer
WO2004022593A2 (en) *	2002-09-09	2004-03-18	Nautilus Biotech	Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2004028472A2 (en) *	2002-09-27	2004-04-08	Biogen Idec Ma Inc.	THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β
EP1581631A4 (en) *	2002-10-01	2007-09-05	Xencor Inc	INTERFERON VARIANTS HAVING IMPROVED PROPERTIES
JP5452835B2 (ja) *	2003-07-15	2014-03-26	中外製薬株式会社	形質転換細胞によるＩｇＭの産生とその定量方法
AU2004271200A1 (en) *	2003-09-05	2005-03-17	Gtc Biotherapeutics, Inc.	Method for the production of fusion proteins in transgenic mammal milk
ATE518888T1 (de)	2003-10-09	2011-08-15	Chugai Pharmaceutical Co Ltd	Stabilisierte lösung mit hoher igm-konzentration
US8110665B2 (en)	2003-11-13	2012-02-07	Hanmi Holdings Co., Ltd.	Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
MXPA05007210A (es)	2003-11-13	2006-02-10	Hanmi Pharm Ind Co Ltd	Complejo de proteina que usa un fragmento de inmunoglobulina y metodo para la preparacion del mismo.
JP2007519422A (ja)	2004-02-02	2007-07-19	アンブレツクス・インコーポレイテツド	修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
CA2556339A1 (en) *	2004-03-01	2005-09-15	David Ray Filpula	Interferon-beta polymer conjugates
WO2005120540A2 (en) *	2004-06-09	2005-12-22	Schering Aktiengesellschaft	Interferon alpha or beta for treatment of cardiomyopathy and endothelial dysfunction
US7670595B2 (en) *	2004-06-28	2010-03-02	Merck Patent Gmbh	Fc-interferon-beta fusion proteins
WO2009100255A2 (en)	2008-02-08	2009-08-13	Ambrx, Inc.	Modified leptin polypeptides and their uses
JP5192823B2 (ja)	2005-01-12	2013-05-08	バイオジェン・アイデック・エムエイ・インコーポレイテッド	インターフェロン−βを送達するための方法
CA2616479A1 (en)	2005-09-01	2007-03-08	Ares Trading S.A.	Treatment of optic neuritis
US9458444B2 (en)	2006-02-03	2016-10-04	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
US10351615B2 (en)	2006-02-03	2019-07-16	Opko Biologics Ltd.	Methods of treatment with long-acting growth hormone
US20150038413A1 (en)	2006-02-03	2015-02-05	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en)	2006-02-03	2014-04-24	Prolor Biotech Ltd.	Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en)	2006-02-03	2015-02-03	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US8476234B2 (en)	2006-02-03	2013-07-02	Prolor Biotech Inc.	Long-acting coagulation factors and methods of producing same
US9249407B2 (en)	2006-02-03	2016-02-02	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
US8759292B2 (en)	2006-02-03	2014-06-24	Prolor Biotech, Llc	Long-acting coagulation factors and methods of producing same
US8048849B2 (en)	2006-02-03	2011-11-01	Modigene, Inc.	Long-acting polypeptides and methods of producing same
US7553940B2 (en)	2006-02-03	2009-06-30	Modigene Inc	Long-acting EPO polypeptides and derivatives thereof and methods thereof
US10221228B2 (en)	2006-02-03	2019-03-05	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en)	2006-02-03	2013-05-28	Prolor Biotech Ltd.	Long-acting growth hormone and methods of producing same
US20080038224A1 (en) *	2006-03-28	2008-02-14	Thierry Guyon	Modified interferon-beta (IFN-beta) polypeptides
US9283260B2 (en)	2006-04-21	2016-03-15	Amgen Inc.	Lyophilized therapeutic peptibody formulations
AU2007253254B2 (en)	2006-05-24	2013-01-17	Merck Serono Sa	Cladribine regimen for treating multiple sclerosis
US8414897B1 (en) *	2006-10-02	2013-04-09	The Uab Research Foundation	Pathway for Th-17 cell development and methods utilizing same
FR2907454B1 (fr) *	2006-10-18	2009-01-23	Biomethodes Sa	Variants ameliores de l'interferon beta humain
JP2010525821A (ja)	2007-05-02	2010-07-29	アンブルックス，インコーポレイテッド	修飾ＩＦＮβポリペプチドおよびこれらの使用
US20090304719A1 (en)	2007-08-22	2009-12-10	Patrick Daugherty	Activatable binding polypeptides and methods of identification and use thereof
CN103880965B (zh) *	2007-09-21	2018-02-16	加利福尼亚大学董事会	被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
US20100203009A1 (en) *	2007-10-02	2010-08-12	The Uab Research Foundation	Pathway for Th-17 Cell Development and Methods Utilizing Same
EP2203180B1 (en) *	2007-10-22	2012-11-21	Merck Serono S.A.	Single ifn-beta fused to a mutated igg fc fragment
CA2731546C (en)	2008-07-23	2013-11-19	Hanmi Holdings Co., Ltd.	A polypeptide complex comprising non-peptidyl polymer having three functional ends
ES2963062T3 (es)	2008-07-23	2024-03-25	Ambrx Inc	Polipéptidos G-CSF bovinos modificados y sus usos
EP2385955B1 (en)	2009-01-12	2020-08-12	CytomX Therapeutics, Inc.	Modified antibody compositions, methods of making and using thereof
BRPI1011384A2 (pt)	2009-02-23	2016-03-15	Cytomx Therapeutics Inc	pro-proteinas e seus metodos de uso
EA201171259A1 (ru)	2009-04-22	2012-05-30	Мерк Патент Гмбх	Антительные гибридные белки с модифицированными сайтами связывания fcrn
US9663778B2 (en)	2009-07-09	2017-05-30	OPKO Biologies Ltd.	Long-acting coagulation factors and methods of producing same
US12203113B2 (en)	2009-07-09	2025-01-21	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
BR112012015597A2 (pt)	2009-12-21	2017-01-31	Ambrx Inc	peptídeos de somatotropina suínos modificados e seus usos
NZ600361A (en)	2009-12-21	2014-06-27	Ambrx Inc	Modified bovine somatotropin polypeptides and their uses
DK2533634T3 (en) *	2010-02-12	2016-01-25	Biogen Ma Inc	NEURO PROTECTIVE demyelinating diseases
WO2011106234A1 (en)	2010-02-25	2011-09-01	Provasculon, Inc.	Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
AR080993A1 (es) *	2010-04-02	2012-05-30	Hanmi Holdings Co Ltd	Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
TWI480288B (zh)	2010-09-23	2015-04-11	Lilly Co Eli	牛顆粒細胞群落刺激因子及其變體之調配物
WO2012170495A1 (en) *	2011-06-07	2012-12-13	Provasculon, Inc.	Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
CA2850469C (en) *	2011-10-01	2020-07-07	Glytech, Inc.	Glycosylated polypeptide and pharmaceutical composition containing same
JP6184965B2 (ja)	2011-10-28	2017-08-23	テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド	ポリペプチド構築物およびその使用
EA201491898A1 (ru)	2012-04-19	2015-08-31	Опко Байолоджикс Лтд.	Варианты оксинтомодулина пролонгированного действия и способы получения указанных вариантов
US9783589B2 (en) *	2012-08-13	2017-10-10	Immungene Inc	Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
EP3848386A1 (en)	2012-11-20	2021-07-14	OPKO Biologics Ltd.	Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
WO2014089354A1 (en)	2012-12-07	2014-06-12	The Regents Of The University Of California	Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
KR102073748B1 (ko)	2013-01-31	2020-02-05	한미약품 주식회사	재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
AU2014245917B2 (en)	2013-03-29	2017-09-28	Glytech, Inc.	Polypeptide having sialylated sugar chains attached thereto
KR102094022B1 (ko)	2013-04-29	2020-03-30	테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디	항-cd38 항체 및 감쇠 인터페론 알파-2ｂ와의 융합체
US11117975B2 (en)	2013-04-29	2021-09-14	Teva Pharmaceuticals Australia Pty Ltd	Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
CN106967175A (zh) *	2013-05-15	2017-07-21	复旦大学	长效干扰素及其制备方法和用途
US10093745B2 (en)	2013-05-29	2018-10-09	The Regents Of The University Of California	Anti-CSPG4 fusions with interferon for the treatment of malignancy
AR096891A1 (es)	2013-07-12	2016-02-03	Hanmi Pharm Ind Co Ltd	Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
US20150158926A1 (en)	2013-10-21	2015-06-11	Opko Biologics, Ltd.	Long-acting polypeptides and methods of producing and administering same
JP6618912B2 (ja)	2013-12-20	2019-12-11	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	改良された、組換えポリペプチド作製方法
UA119352C2 (uk)	2014-05-01	2019-06-10	Тева Фармасьютикалз Острейліа Пті Лтд	Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
UA125637C2 (uk)	2014-10-29	2022-05-11	Тева Фармасьютікалз Острейліа Пті Лтд	ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b
RU2743295C2 (ru)	2014-12-10	2021-02-16	Опко Байолоджикс Лтд.	Способы производства стр-модифицированных полипептидов гормона роста длительного действия
EP3310347B1 (en)	2015-06-19	2021-08-04	OPKO Biologics Ltd.	Long-acting coagulation factors and methods of producing same
IL302486A (en)	2015-06-24	2023-06-01	Hoffmann La Roche	Antibodies against the transnephrine receptor with adapted affinity
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
KR20250007038A (ko)	2015-10-02	2025-01-13	에프. 호프만-라 로슈 아게	이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법
US11236141B2 (en) *	2016-05-13	2022-02-01	Orionis Biosciences BV	Targeted mutant interferon-beta and uses thereof
US11976106B2 (en)	2016-07-11	2024-05-07	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
WO2019101960A1 (en)	2017-11-24	2019-05-31	Merck Patent Gmbh	Cladribine regimen for use intreating progressive forms of multiple sclerosis
AU2021210773B2 (en) *	2020-01-23	2024-11-07	Genexine, Inc.	Fusion protein comprising pd-l1 protein and use thereof
EP4126009A4 (en) *	2020-04-03	2024-04-17	The University of North Carolina at Chapel Hill	BINDING PROTEINS FOR USE AGAINST ACE2-TARGETED VIRUSES
JP7695719B2 (ja) *	2020-07-01	2025-06-19	中国科学院生物物理研究所	融合タンパク質ワクチンプラットフォームの構築と応用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3359030A (en) *	1966-12-16	1967-12-19	Newman George	Bumper guard assembly
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4002531A (en)	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
US4414147A (en)	1981-04-17	1983-11-08	Massachusetts Institute Of Technology	Methods of decreasing the hydrophobicity of fibroblast and other interferons
WO1983002461A1 (en) *	1982-01-19	1983-07-21	Cetus Corp	Multiclass hybrid interferons
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
US4609546A (en)	1982-06-24	1986-09-02	Japan Chemical Research Co., Ltd.	Long-acting composition
GB8334102D0 (en)	1983-12-21	1984-02-01	Searle & Co	Interferons with cysteine pattern
DE3572982D1 (en)	1984-03-06	1989-10-19	Takeda Chemical Industries Ltd	Chemically modified lymphokine and production thereof
GB8412564D0 (en) *	1984-05-17	1984-06-20	Searle & Co	Structure and properties
JP2524586B2 (ja)	1985-06-26	1996-08-14	シタスコーポレイション	ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4917888A (en)	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) *	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4935233A (en) *	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
JP2514950B2 (ja)	1986-03-10	1996-07-10	エフ・ホフマン―ラロシユアーゲー	化学修飾蛋白質，その製造法および中間体
JPS63152393A (ja)	1986-07-03	1988-06-24	Takeda Chem Ind Ltd	グリコシル誘導体
US4868802A (en) *	1986-07-28	1989-09-19	Kabushiki Kaisha Toshiba	Magnetooptic recording and erasing head which performs biasing, tracking and focusing
US4894226A (en)	1986-11-14	1990-01-16	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4904584A (en)	1987-12-23	1990-02-27	Genetics Institute, Inc.	Site-specific homogeneous modification of polypeptides
US4847325A (en)	1988-01-20	1989-07-11	Cetus Corporation	Conjugation of polymer to colony stimulating factor-1
CA1340810C (en)	1988-03-31	1999-11-02	Motoo Yamasaki	Polypeptide derivatives of human granulocyte colony stimulating factor
AU4660789A (en)	1988-11-23	1990-06-12	Genentech Inc.	Polypeptide derivatives
EP0401384B1 (en)	1988-12-22	1996-03-13	Kirin-Amgen, Inc.	Chemically modified granulocyte colony stimulating factor
US5116964A (en) *	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5286637A (en)	1989-08-07	1994-02-15	Debiopharm, S.A.	Biologically active drug polymer derivatives and method for preparing same
JPH04218000A (ja)	1990-02-13	1992-08-07	Kirin Amgen Inc	修飾ポリペプチド
US5252714A (en)	1990-11-28	1993-10-12	The University Of Alabama In Huntsville	Preparation and use of polyethylene glycol propionaldehyde
DE69233069T2 (de)	1991-03-15	2003-11-27	Amgen Inc., Thousand Oaks	Pegylation von polypeptiden
US5595732A (en)	1991-03-25	1997-01-21	Hoffmann-La Roche Inc.	Polyethylene-protein conjugates
AU2147192A (en)	1991-06-28	1993-01-25	Genentech Inc.	Method of stimulating immune response using growth hormone
US5281698A (en)	1991-07-23	1994-01-25	Cetus Oncology Corporation	Preparation of an activated polymer ester for protein conjugation
AU3423293A (en)	1991-12-19	1993-07-19	Baylor College Of Medicine	Pva or peg conjugates of peptides for epitope-specific immunosuppression
ZA933926B (en)	1992-06-17	1994-01-03	Amgen Inc	Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5255519A (en)	1992-08-14	1993-10-26	Millennium Technologies, Inc.	Method and apparatus for increasing efficiency and productivity in a power generation cycle
US5382657A (en)	1992-08-26	1995-01-17	Hoffmann-La Roche Inc.	Peg-interferon conjugates
WO1994005332A2 (en)	1992-09-01	1994-03-17	Berlex Laboratories, Inc.	Glycolation of glycosylated macromolecules
US5298410A (en)	1993-02-25	1994-03-29	Sterling Winthrop Inc.	Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5681811A (en)	1993-05-10	1997-10-28	Protein Delivery, Inc.	Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en)	1993-05-10	1994-10-25	Protein Delivery, Inc.	Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5874075A (en)	1993-10-06	1999-02-23	Amgen Inc.	Stable protein: phospholipid compositions and methods
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5951974A (en)	1993-11-10	1999-09-14	Enzon, Inc.	Interferon polymer conjugates
AU691225B2 (en)	1993-11-10	1998-05-14	Schering Corporation	Improved interferon polymer conjugates
PT726778E (pt)	1994-02-08	2001-12-28	Amgen Inc	Sistema de administracao oral de proteinas g-csf modificadas quimicamente
US5545723A (en)	1994-03-15	1996-08-13	Biogen Inc.	Muteins of IFN-β
GB9415379D0 (en) *	1994-07-29	1994-09-21	Smithkline Beecham Plc	Novel compounds
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5738846A (en)	1994-11-10	1998-04-14	Enzon, Inc.	Interferon polymer conjugates and process for preparing the same
EP0796324A1 (en)	1994-12-07	1997-09-24	Novo Nordisk A/S	Polypeptide with reduced allergenicity
US5672662A (en)	1995-07-07	1997-09-30	Shearwater Polymers, Inc.	Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
KR0154850B1 (ko) *	1995-10-09	1998-10-15	김광호	바이씨모스 및 그의 제조방법
US5702717A (en)	1995-10-25	1997-12-30	Macromed, Inc.	Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5908621A (en)	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
US5723125A (en) *	1995-12-28	1998-03-03	Tanox Biosystems, Inc.	Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US5747639A (en)	1996-03-06	1998-05-05	Amgen Boulder Inc.	Use of hydrophobic interaction chromatography to purify polyethylene glycols
ATE200030T1 (de)	1997-01-29	2001-04-15	Polymasc Pharmaceuticals Plc	Pegylationsverfahren
US5990237A (en)	1997-05-21	1999-11-23	Shearwater Polymers, Inc.	Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
IL133974A0 (en)	1997-07-14	2001-04-30	Bolder Biotechnology Inc	Derivatives of growth hormone and related proteins
US6180095B1 (en)	1997-12-17	2001-01-30	Enzon, Inc.	Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5985263A (en)	1997-12-19	1999-11-16	Enzon, Inc.	Substantially pure histidine-linked protein polymer conjugates
US5981709A (en)	1997-12-19	1999-11-09	Enzon, Inc.	α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5965119A (en)	1997-12-30	1999-10-12	Enzon, Inc.	Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
ATE399809T1 (de)	1998-03-12	2008-07-15	Nektar Therapeutics Al Corp	Verfahren zur herstellung von polymerkonjugaten
WO1999055377A2 (en)	1998-04-28	1999-11-04	Applied Research Systems Ars Holding N.V.	Polyol-ifn-beta conjugates
US6703381B1 (en)	1998-08-14	2004-03-09	Nobex Corporation	Methods for delivery therapeutic compounds across the blood-brain barrier
EE05201B1 (et) *	1998-10-16	2009-08-17	Biogen Idec Ma Inc.	Glkoslitud interferoon-beeta, selle kasutamine ja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
EE05111B1 (et) *	1998-10-16	2008-12-15	Biogen, Incorporated	Interferoon-beetaga sulandatud valgud ja nende kasutamine
BR0013638A (pt)	1999-08-27	2002-05-14	Maxygen Aps	Novas moléculas semelhantes a interferon beta
DE60026073T2 (de)	1999-12-22	2006-09-28	Nektar Therapeutics Al, Corp., Huntsville	Sterisch gehinderte derivate von wasserlöslichen polymeren
US20080033818A1 (en)	2005-03-17	2008-02-07	Inc2 Webcom Ltd.	Real time interactive response system and methods

1999
- 1999-10-15 EE EEP200100223A patent/EE05111B1/et not_active IP Right Cessation
- 1999-10-15 HK HK02103895.8A patent/HK1042098B/zh not_active IP Right Cessation
- 1999-10-15 AU AU13158/00A patent/AU766190B2/en not_active Ceased
- 1999-10-15 AT AT99956574T patent/ATE327254T1/de active
- 1999-10-15 EA EA200100447A patent/EA005005B1/ru not_active IP Right Cessation
- 1999-10-15 IL IL14235099A patent/IL142350A0/xx active IP Right Grant
- 1999-10-15 NZ NZ510559A patent/NZ510559A/en not_active IP Right Cessation
- 1999-10-15 KR KR1020017004797A patent/KR100767649B1/ko not_active Expired - Fee Related
- 1999-10-15 WO PCT/US1999/024200 patent/WO2000023472A2/en not_active Ceased
- 1999-10-15 JP JP2000577197A patent/JP4761621B2/ja not_active Expired - Fee Related
- 1999-10-15 HU HU0200414A patent/HUP0200414A2/hu unknown
- 1999-10-15 DK DK99956574T patent/DK1121382T3/da active
- 1999-10-15 PL PL347932A patent/PL200586B1/pl not_active IP Right Cessation
- 1999-10-15 CA CA002343094A patent/CA2343094A1/en not_active Abandoned
- 1999-10-15 ES ES99956574T patent/ES2265693T3/es not_active Expired - Lifetime
- 1999-10-15 CN CNB998122130A patent/CN100480266C/zh not_active Expired - Fee Related
- 1999-10-15 SK SK510-2001A patent/SK287491B6/sk not_active IP Right Cessation
- 1999-10-15 MX MXPA01003790A patent/MXPA01003790A/es not_active IP Right Cessation
- 1999-10-15 EP EP99956574A patent/EP1121382B9/en not_active Expired - Lifetime
- 1999-10-15 DE DE69931507T patent/DE69931507T2/de not_active Expired - Lifetime
- 1999-10-15 CZ CZ20011330A patent/CZ300762B6/cs not_active IP Right Cessation
- 1999-10-15 TR TR2001/01087T patent/TR200101087T2/xx unknown
- 1999-10-15 BR BR9915548-6A patent/BR9915548A/pt not_active Application Discontinuation
- 1999-10-15 PT PT99956574T patent/PT1121382E/pt unknown
2001
- 2001-03-14 IS IS5887A patent/IS5887A/is unknown
- 2001-04-01 IL IL142350A patent/IL142350A/en not_active IP Right Cessation
- 2001-04-11 US US09/832,659 patent/US6800735B2/en not_active Expired - Fee Related
- 2001-04-11 NO NO20011861A patent/NO20011861L/no unknown
2004
- 2004-06-15 US US10/868,673 patent/US7527946B2/en not_active Expired - Fee Related
2006
- 2006-08-24 CY CY20061101194T patent/CY1105173T1/el unknown
2009
- 2009-03-18 US US12/406,387 patent/US20090286958A1/en not_active Abandoned
2010
- 2010-07-22 JP JP2010165349A patent/JP2010268810A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
IS5887A (is)	2001-03-14
AU1315800A (en)	2000-05-08
NO20011861L (no)	2001-06-13
PT1121382E (pt)	2006-10-31
HK1042098B (zh)	2009-10-30
JP2002527100A (ja)	2002-08-27
KR20010085932A (ko)	2001-09-07
CA2343094A1 (en)	2000-04-27
KR100767649B1 (ko)	2007-10-17
NO20011861D0 (no)	2001-04-11
EP1121382B1 (en)	2006-05-24
SK5102001A3 (en)	2003-03-04
US20090286958A1 (en)	2009-11-19
CZ20011330A3 (cs)	2001-09-12
SK287491B6 (sk)	2010-11-08
HUP0200414A2 (en)	2002-06-29
HK1042098A1 (zh)	2002-08-02
US20050214253A1 (en)	2005-09-29
EA200100447A1 (ru)	2001-10-22
AU766190B2 (en)	2003-10-09
MXPA01003790A (es)	2002-09-18
TR200101087T2 (tr)	2001-09-21
ATE327254T1 (de)	2006-06-15
CN100480266C (zh)	2009-04-22
JP4761621B2 (ja)	2011-08-31
CZ300762B6 (cs)	2009-08-05
IL142350A0 (en)	2002-03-10
PL347932A1 (en)	2002-04-22
US6800735B2 (en)	2004-10-05
IL142350A (en)	2007-07-04
DE69931507T2 (de)	2007-01-11
CN1333785A (zh)	2002-01-30
ES2265693T3 (es)	2007-02-16
CY1105173T1 (el)	2010-03-03
PL200586B1 (pl)	2009-01-30
US7527946B2 (en)	2009-05-05
DK1121382T3 (da)	2006-11-13
EA005005B1 (ru)	2004-10-28
EE200100223A (et)	2002-06-17
DE69931507D1 (de)	2006-06-29
WO2000023472A3 (en)	2000-08-31
JP2010268810A (ja)	2010-12-02
BR9915548A (pt)	2001-08-14
US20020155547A1 (en)	2002-10-24
EP1121382B9 (en)	2007-07-04
WO2000023472A2 (en)	2000-04-27
EP1121382A2 (en)	2001-08-08
NZ510559A (en)	2003-12-19

Publication	Publication Date	Title
EE05111B1 (et)	2008-12-15	Interferoon-beetaga sulandatud valgud ja nende kasutamine
ES2149149T1 (es)	2000-11-01	Proteinas de fijacion de interleuquina-18, su preparacion y utilizacion.
TR199600357A2 (tr)	1996-11-21	Rekombinant simanlik (Ob) proteinleri.
ATE339507T1 (de)	2006-10-15	Erythropoietin-analog-menschliches serum-albumin fusionsprotein
ATE402957T1 (de)	2008-08-15	Analoge des menschlichen interferon-alpha mit niedriger toxizität
TR199501669A1 (tr)	1997-03-21	Peptid ve proteinlerin aerosol formülasyonlari.
ATE103932T1 (de)	1994-04-15	Fusionsprotein bestehend aus gm-csf und il-3.
NZ503850A (en)	2002-12-20	April - a novel protein with growth effects
DE69823046D1 (de)	2004-05-13	Praktische in vitro sialylierung von rekombinanten glykpproteinen
WO2001025438A3 (en)	2002-07-11	Ifn-alpha homologues
EP1739090A3 (en)	2009-04-08	Interferon-beta fusion proteins and uses
NO20005081D0 (no)	2000-10-09	Et polypeptid inneholdende aminosyren fra et N-terminalt kolinbindende protein A-truncat, vaksine avledet derfra og anvendelser derav
GB2336844B (en)	2001-09-26	Anti-hiv peptides and proteins
EE200000694A (et)	2002-06-17	Inimese rekombinantse iterferooni beeta-1a (IFN-ß-1a) formulatsioon
NO20005547D0 (no)	2000-11-03	Myelinbasiske proteinpeptider og anvendelser derav
DK0490383T3 (da)	1997-02-17	Peptider af HIV-gag-proteinet, fremstilling og anvendelse deraf
EP0723016A3 (en)	1997-08-20	Leukocyte activation factor
DK0938555T3 (da)	2005-05-23	Konstruktioner og komplekser af cyclin E
AU4956901A (en)	2001-10-08	Novel human 7tm proteins and polynucleotides encoding the same
MY114223A (en)	2002-09-30	Fusion proteins comprising gm-csf and il-3
ATE404576T1 (de)	2008-08-15	Neuartiges polypeptid und dessen kodierende nukleinsäuren

Legal Events

Date	Code	Title	Description
2005-08-15	HC1A	Change of owner name
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231
2013-06-17	MM4A	Lapsed by not paying the annual fees	Effective date: 20121015